A novel platform for attenuating immune hyperactivity using EXO‐CD24 in COVID‐19 and beyond
Sign Up to like & getrecommendations! Published in 2022 at "EMBO Molecular Medicine"
DOI: 10.15252/emmm.202215997
Abstract: A small but significant proportion of COVID‐19 patients develop life‐threatening cytokine storm. We have developed a new anti‐inflammatory drug, EXO‐CD24, a combination of an immune checkpoint (CD24) and a delivery platform (exosomes). CD24 inhibits the… read more here.
Keywords: platform attenuating; novel platform; exo cd24; covid ... See more keywords